Pacritinib

別名:SB1518

Pacritinib is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.

Pacritinib化学構造

CAS No. 937272-79-2

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 66600 国内在庫あり
JPY 51300 国内在庫あり
JPY 249300 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(15)

カスタマーフィードバック1个实验数据

製品安全説明書

現在のバッチを見る: 純度: 99.94%
99.94

Pacritinibと併用されることが多い化合物

Fedratinib (TG101348)


Pacritinib and Fedratinib are JAK inhibitors that have been approved for the treatment of myelofibrosis.

Waksal JA, et al. Curr Hematol Malig Rep. 2022 Oct;17(5):140-154.

TMZ(Temozolomide)


Pacritinib and Temozolomide use shows BBB penetration and improves overall median survival in an orthotopic xenograft mice model.

Jensen KV, et al. PLoS One. 2017 Dec 18;12(12):e0189670.

Rapamycin (Sirolimus)


Pacritinib and Sirolimus use enhances suppression over human T cells in xenogeneic GVHD models and in vitro.

Pidala J, et al. Clin Cancer Res. 2021 May 15;27(10):2712-2722.

Ruxolitinib


Pacritinib protects the differentiation and upregulation of costimulatory molecules of human dendritic cells (DCs), whereas ruxolitinib heavily impairs their differentiation and function.

Heine A, et al. Exp Hematol. 2021 Aug;100:37-40.

Pracinostat (SB939)


Pacritinib and Pracinostat completely abrogate the JAK2-autophosphorylation and enhance cell death in Set-2 cells.

Novotny-Diermayr V, et al. Blood Cancer J. 2012 May;2(5):e69.

Pacritinib関連製品

シグナル伝達経路

JAK阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
KMS-12-BM Function assay 2 uM 3 hrs Inhibition of JAK2 in IL-6-stimulated human KMS-12-BM cells assessed as suppression of STAT3 phosphorylation at TY705 residue at 2 uM pretreated for 3 hrs followed by IL-6 stimulation by immunoblot method 27541357
MOLM14 Function assay 0.1 uM 3 hrs Inhibition of JAK2 in IL-6-stimulated human MOLM14 cells assessed as suppression of STAT3 phosphorylation at TY705 residue at 0.1 uM pretreated for 3 hrs followed by IL-6 stimulation by immunoblot method 27541357
TAMH Cytotoxicity assay 24 hrs Cytotoxicity against TAMH cells assessed as cell viability after 24 hrs by CellTiter-Glo assay, IC50 = 3.68 μM. 28953386
AC10 Cytotoxicity assay 24 hrs Cytotoxicity against human AC10 cells assessed as cell viability after 24 hrs by CellTiter-Glo assay, IC50 = 2.02 μM. 28953386
NKYS Antiproliferative assay 48 hrs Antiproliferative activity against human NKYS cells after 48 hrs by CellTiter-Glo luminescent assay, IC50 = 1.6 μM. 28953386
KG1 Antiproliferative assay 48 hrs Antiproliferative activity against human KG1 cells after 48 hrs by CellTiter-Glo luminescent assay, IC50 = 1.48 μM. 28953386
KHYG Antiproliferative assay 48 hrs Antiproliferative activity against human KHYG cells after 48 hrs by CellTiter-Glo luminescent assay, IC50 = 1.24 μM. 28953386
OPM2 Antiproliferative assay 48 hrs Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo luminescent assay, IC50 = 1.21 μM. 28953386
HEL 92.1.7 Antiproliferative assay 36 hrs Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay, IC50 = 1.17 μM. 28953386
KMS-12-BM Antiproliferative assay 48 hrs Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo luminescent assay, IC50 = 0.75 μM. 28953386
MOLM14 Antiproliferative assay 48 hrs Antiproliferative activity against human MOLM14 cells after 48 hrs by CellTiter-Glo luminescent assay, IC50 = 0.079 μM. 28953386
TAMH Antiproliferative assay 24 hrs Antiproliferative activity against mouse TAMH cells after 24 hrs by CellTiter-Glo assay, IC50 = 3.68 μM. 27541357
PC3 Antiproliferative assay 72 hrs Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay, IC50 = 2.41 μM. 27541357
MDA-MB-231 Antiproliferative assay 72 hrs Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 2.43 μM. 27541357
HEL 92.1.7 Antiproliferative assay 48 hrs Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 48 hrs by CellTiter-Glo assay, IC50 = 1.726 μM. 27541357
HCT116 Antiproliferative assay 48 hrs Antiproliferative activity against human HCT116 cells after 48 hrs by CellTiter-Glo assay, IC50 = 1.69 μM. 27541357
NKYS Antiproliferative assay 48 hrs Antiproliferative activity against human NKYS cells after 48 hrs by CellTiter-Glo assay, IC50 = 1.6 μM. 27541357
KG1 Antiproliferative assay 48 hrs Antiproliferative activity against human KG1 cells after 48 hrs by CellTiter-Glo assay, IC50 = 1.48 μM. 27541357
KHYG Antiproliferative assay 48 hrs Antiproliferative activity against human KHYG cells after 48 hrs by CellTiter-Glo assay, IC50 = 1.24 μM. 27541357
OPM2 Antiproliferative assay 48 hrs Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo assay, IC50 = 1.21 μM. 27541357
HEL 92.1.7 Antiproliferative assay 36 hrs Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay, IC50 = 1.17 μM. 27541357
HCT116 Antiproliferative assay 72 hrs Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 0.88 μM. 27541357
MCF7 Antiproliferative assay 48 hrs Antiproliferative activity against human MCF7 cells after 48 hrs by CellTiter-Glo assay, IC50 = 0.85 μM. 27541357
Jurkat Antiproliferative assay 48 hrs Antiproliferative activity against human Jurkat cells after 48 hrs by CellTiter-Glo assay, IC50 = 0.839 μM. 27541357
PC3 Antiproliferative assay 48 hrs Antiproliferative activity against human PC3 cells after 48 hrs by CellTiter-Glo assay, IC50 = 0.77 μM. 27541357
KMS-12-BM Antiproliferative assay 48 hrs Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo assay, IC50 = 0.75 μM. 27541357
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 0.29 μM. 27541357
HL60 Antiproliferative assay 48 hrs Antiproliferative activity against human HL60 cells after 48 hrs by CellTiter-Glo assay, IC50 = 0.52 μM. 27541357
MOLM14 Antiproliferative assay 48 hrs Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutant after 48 hrs by CellTiter-Glo assay, IC50 = 0.079 μM. 27541357
HEL 92.1.7 Function assay 1 hr Induction of JAK2 V617F mutant phosphorylation at Y1007/8 residues in HEL 92.1.7 cells after 1 hr by immunoblot method 27541357
HL60 Antiproliferative assay Antiproliferative activity against human HL60 cells, IC50 = 1.78 μM. 28953386
Jurkat Antiproliferative assay Antiproliferative activity against human Jurkat cells, IC50 = 1.09 μM. 28953386
HL60 Antiproliferative assay Antiproliferative activity against human HL60 cells, IC50 = 1.78 μM. 27541357
Jurkat Antiproliferative assay Antiproliferative activity against human Jurkat cells, IC50 = 1.09 μM. 27541357
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Pacritinib is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.
特性 Dual JAK2/FLT3 inhibitor that has progressed to Phase III clinical trials for treatment of Myelofibrosis.
Targets
FLT3 (D835Y) [1]
(Cell-free assay)
JAK2 (V617F) [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
JAK2 [1]
(Cell-free assay)
TYK2 [1]
(Cell-free assay)
もっとクリックする
6 nM 19 nM 22 nM 23 nM 50 nM
In Vitro
In vitro Pacritinib is a potent inhibitor of both wild-type JAK2 and JAK2V617F mutant (IC50= 19 nM) that is present in high frequencies among patients with MPD. Relative to JAK2, Pacritinib is two-fold less potent against TYK2 (IC50= 50 nM), 23-fold less potent against JAK3 (IC50= 520 nM) and 56-fold less potent against JAK1 (IC50= 1280 nM). Pacritinib effectively permeates cells to modulate signaling pathways downstream of JAK2, whether agonist activated or mutationally activated. Pacritinib induces apoptosis, cell cycle arrest and antiproliferative effects in JAK2WT- and JAK2V617F-dependent cells. Pacritinib inhibits cell proliferation of Karpas 1106P and Ba/F3-JAK2V617F with IC50 of 348 and 160 nM, respectively. Pacritinib inhibits endogenous colony growth derived from erythroid and myeloid progenitors with IC50 of 63 and 53 nM , respectively. [1] SB1518 also inhibits FLT3 and its mutant FLT3-D835Y(IC50= 6 nM ). Pacritinib inhibits FLT3 phosphorylation and downstream STAT, MAPK and PI3K signaling in FLT3-internal-tandem duplication (ITD), FLT3-wt cells and primary AML blast cells. Pacritinib treatment leads to a dose-dependent decrease of pFLT3, pSTAT5, pERK1/2 and pAkt in FLT3-ITD harboring MV4-11 cells with IC50 of 80, 40, 33 and 29 nM , respectively. Treatment of the primary AML blast cells with Pacritinib for 3 h leads to a dose-dependent decrease of pFLT3, pSTAT3 and pSTAT5 with an IC50 below 0.5 μM. Pacritinib induces apoptosis, cell cycle arrest and anti-proliferative effects in FLT3-mutant and FLT3-wt cells. Pacritinib inhibits cell proliferation of FLT3-ITD-harboring cells MV4-11 and primary AML blast cells with IC50s of 47 nM and 0.19-1.3 μM, respectively. [2]
Kinase Assay kinase activity assays
All assays are carried out in 384-well white microtiter plates. Compounds are 4-fold serially diluted in 8 steps, starting from 10 μM. The reaction mixture consisted of 25 μL assay buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 5 mM β-glycerol phosphate). For FLT3 assays, the reaction contains 2.0 μg/mL FLT3 enzyme, 5 μM of poly(Glu,Tyr) substrate and 4 μM of ATP. For JAK1 assays, the reaction contains 2.5 μg/mL of JAK1 enzyme, 10 μM of poly(Glu,Ala,Tyr) substrate and 1.0 μM of ATP. For JAK2 assays, the reaction contained 0.35 μg/mL of JAK2 enzyme, 10 μM of poly (Glu,Ala,Tyr) substrate and 0.15 μM of ATP. For JAK3 assays, the reaction contained 3.5 μg/mL of JAK3 enzyme, 10 μM of poly (Glu,Ala,Tyr) substrate and 6.0 μM of ATP. For TYK2 assays, the reaction contained 2.5 μg/mL of TYK2 enzyme, 10 μM of poly (Glu,Ala,Tyr) substrate and 0.15 μM of ATP. The reaction is incubated at room temperature for 2 h prior to addition of 13 μL PKLight® detection reagent. After 10 min incubation luminescent signals are read on a multi-label plate reader.
細胞実験 細胞株 Karpas 1106P cells
濃度 ~10 μM
反応時間 2 days
実験の流れ Cells are seeded at 30-50% confluency in 96-well plates and are treated with different concentrations of compounds (in triplicate) for 48 h. Cell viability is monitored using the CellTiter-Glo assay.
実験結果図 Methods Biomarkers 結果図 PMID
Western blot pFLT3(Y591) / pSTAT5(Y694) / pERK1、2 / pAkt(T308) / β-Actin pFLT3(Y591) / pSTAT5(Y694) / pERK1、2 / pAkt(T308) / β-Actin pSTAT3 Y705 / STAT3 / Actin / MAPK / p-AKT S473 / AKT pSTAT3 Y705 / STAT3 / β-Tubulin p-STAT3Y705 / STAT3 / ACTIN / PARP pFLT3 / FLT3 / pSTAT5 / STAT5 / GAPDH 22829080
Growth inhibition assay Cell viability 29235481
IHC p-STAT3 / Ki-67 / mCD31 / VEGF-A / Bcl-2 HE staining of skin grafts HE staining of liver sections 32929154
Immunofluorescence TUNEL Phalloidin 32929154
In Vivo
In Vivo Pacritinib administrated at 150 mg/kg p.o. q.d. to JAK2V617F-dependent xenograft model, significantly ameliorates splenomegaly and hepatomegaly symptoms, with 60% normalization of spleen weight and 92% normalization of liver weight and is well tolerated without significant weight loss or any hematological toxicities, including thrombocytopenia and anemia. Pacritinib induces dose-dependent inhibition of tumor growth of JAK2V617F-dependent SET-2 xenograft model (40% for 75 mg/kg and 61% for 150 mg/kg). [1] Pacritinib is efficacious in FLT3-ITD-bearing MV4-11 xenograft models. Pacritinib treated once daily for 21 consecutive days, induces dose-dependent inhibition of tumor growth (38% for 25 mg/kg, 92% for 50 mg/kg and 121% for 100 mg/kg). Complete regression is observed in 3/10 and 8/8 mice for the 50 and 100 mg/kg/day groups, respectively. [2]
動物実験 動物モデル Human megakaryoblastic leukemia xenografts SET-2
投与量 150 mg/kg
投与経路 oral gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06159491 Not yet recruiting
Chronic Myelomonocytic Leukemia
Douglas Tremblay|Sobi Inc.|Icahn School of Medicine at Mount Sinai
January 2 2024 Phase 1|Phase 2
NCT06052618 Not yet recruiting
KSHV Inflammatory Cytokine Syndrome (KICS)|Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
January 12 2024 Phase 2
NCT05531786 Recruiting
Graft vs Host Disease
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
March 6 2023 Phase 1|Phase 2
NCT04520269 Unknown status
Breast Cancer
National University Hospital Singapore
July 13 2020 Phase 1|Phase 2

化学情報

分子量 472.58 化学式

C28H32N4O3

CAS No. 937272-79-2 SDF Download Pacritinib SDFをダウンロードする
Smiles C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2
保管

In vitro
Batch:

DMSO : 11 mg/mL ( (23.27 mM); Warmed with 50℃ water bath; 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Pacritinibを買う | Pacritinib ic50 | Pacritinib供給者 | Pacritinibを購入する | Pacritinib費用 | Pacritinib生産者 | オーダーPacritinib | Pacritinib化学構造 | Pacritinib分子量 | Pacritinib代理店